Christopher C. Whitfield

• Spearhead the development and advancement of Temprian Oncology's early-stage assets for melanoma treatment, driving growth and innovation within the organization.

• Provide strategic guidance to foster partnerships and optimize the technology platform, ensuring the successful achievement of phased strategic objectives for ocular melanoma treatment.

• Identify and prioritize untapped product development opportunities in the melanoma space, focusing on market needs and emerging trends.

• Established partnerships with local businesses to support corporate sponsorship programs and community involvement initiatives.

• Established the Gilead South African Affiliate by developing and implementing a comprehensive functional strategy, ensuring full P&L and balance sheet responsibility.
• Drove effective S&OP processes, order cash efficiency and critical alliance management.
• Spearheaded global market expansion through visionary leadership of commercial strategy and execution across 12 African priority countries.
• Achieved strategic partnerships and business development growth by implementing alliance management performance metrics and executing commercial objectives.
• Oversaw the successful launch and demand activation of products in the therapeutic areas of Hepatitis C, B, HIV, Cell/Gene Therapy, and Oncology.
• Advanced Health and Global Equity Strategy by collaborating cross-functionally to develop Gilead Global Health Equity Strategy.
• Managed budget implementations, employee reviews, training, schedules, and contract negotiations.
• Managed a diverse team of professionals, fostering a positive work environment and high employee satisfaction.
• Developed and implemented strategies to increase sales and profitability.
• Cultivated strong relationships with clients, vendors, and partners to ensure long-term success and loyalty.

• Spearheaded the development and establishment of the Amgen South African Affiliate, driving business growth in the Nephrology and Oncology sectors across Africa
• Achieved a 5-year CAGR of 25%, resulting in a multi-million-dollar buyout and recognition as Amgen's Top Growth Affiliate in the international region in 2010.
• Drove year-over-year business growth while leading operations, strategic vision, and long-range planning.
• Optimized resource allocation by identifying areas of improvement and reallocating resources accordingly.
• Provided guidance on talent acquisition strategies, resulting in an exceptional team of professionals.
• Spearheaded merger and acquisition activities, successfully integrating new businesses into the organization's portfolio.

• Commercialized six service streams: Pharmaceutical and Biopharmaceutical, Medical Diagnostics, Medical Devices, Laboratory Equipment, and Digital Imaging. Generated over $SOM in revenue, $SM EBITDA, and employed 180 people.

• Secured multi-million dollar partnership agreements with industry leaders: Eli Lilly and Company, Amgen, Inc., Hitachi Biosciences, Swedish Orphan BioSciences (SOBI), Thermo Fisher Scientific, SightDx, Aspen-Labs Pharma SA, Sense4Baby, Airstrip, GameRead, and GE Medical Equipment Franchise. Commercialized GE ultrasound and MRI machines in government and private markets. Established a GE-certified equipment service center.

• Established a successful business by identifying market needs and developing innovative solutions.

• Strategically negotiated and signed multi-million dollar partnership agreements with industry giants such as Eli Lilly and Company, Amgen, Inc., Hitachi Biosciences, Swedish Orphan BioSciences (SOB!), Thermo Fisher Scientific, SightDx, Aspen-Labs Pharma SA, Sense4Baby, Airstrip, and GameReady.

• Business Acquisition: LABOTEC: Second-largest B2B laboratory supply company in South Africa. Raised $20 Min private equity and VC capital investments to fund business growth and expansion. Established the SightDx rapid malaria detection technology with the largest private South African laboratory company.

o Business Acquisition: Eli Lilly South Africa, Diabetes Division - Successfully executed a 24% buyout of Eli Lilly South Africa.

• Developed and implemented an award-winning, pati_ent-focused CRM program to enhance patient care by integrating insulin delivery, blood glucose monitoring, nursing support, and CRM.

• Achieved significant business growth, leading to a successful exit within five years.

• Recognized as the Endeavor Global High Impact Entrepreneur Fellow in 2007.

• Founded the African Clinical Research Organization (ACRO), the leading independent full-service clinical research organization (CRO) in partnership with the South African Technology Innovation Agency
• Executed phase I- IV patient clinical trials
• Conducted accredited research training to expand the clinical trial base to more diverse doctors.
• Secured major funding with global funders towards impactful pivotal clinical trials.
• Established strong partnerships with key industry players for greater market presence.